{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:25:24Z","timestamp":1786620324270,"version":"build-2736575974"},"reference-count":63,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sobi, Stockholm, Sweden"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMAHP"],"abstract":"<jats:p>Background: Thrombopoietin receptor agonists\u2014romiplostim, eltrombopag and avatrombopag\u2014are commonly used as second-line treatments for immune thrombocytopenia (ITP). Methods: A Markov model was developed to estimate the cost effectiveness of the three TPO-RAs in adults with insufficient response to previous treatment from the perspective of the UK National Health Service (NHS). The model considered the effects of bleeding events, concomitant ITP medications, rescue therapies and treatment related adverse events over a lifetime horizon. Model inputs for effectiveness were based on a network meta-analysis and other published literature on ITP management. Other model inputs included costs (e.g., drug acquisition and administration) and healthcare resource utilisation. Results: Avatrombopag was associated with higher quality-adjusted life-years (QALYs) (10.979) than romiplostim (10.628) and eltrombopag (10.085), producing incremental QALYs of \u22120.351 and \u22120.894, respectively. Avatrombopag was associated with lower total costs (GBP \u00a3319,334) compared with romiplostim (GBP 406,361 [cost saving of GBP 87,027]) and higher total costs compared with eltrombopag (GBP 313,987 [incremental cost of GBP 5347]). Avatrombopag therefore dominated romiplostim (more effective and less expensive) and was cost-effective versus eltrombopag (incremental cost-effectiveness ratio of GBP 5982 per QALY). Conclusions: Avatrombopag is a cost-effective treatment compared with romiplostim and eltrombopag for the second-line treatment of adults with ITP from the perspective of the UK NHS.<\/jats:p>","DOI":"10.3390\/jmahp13020011","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T06:21:38Z","timestamp":1742797298000},"page":"11","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK"],"prefix":"10.3390","volume":"13","author":[{"given":"Nichola","family":"Cooper","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Guterres","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum Ltd., Cambridge CB21 6AD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Pochopie\u0144","sequence":"additional","affiliation":[{"name":"Assignity, 30-415 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koo","family":"Wilson","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, SE-112 76 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"James","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum Ltd., Cambridge CB21 6AD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[{"name":"Department of Public Health, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8827-1469","authenticated-orcid":false,"given":"Anna","family":"Tytu\u0142a","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Department, Putnam PHMR, 30-701 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Rich","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, SE-112 76 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-242X","authenticated-orcid":false,"given":"Daniel","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, SE-112 76 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"ref_1","first-page":"756","article-title":"Clinical practice updates in the management of immune thrombocytopenia","volume":"42","author":"Khan","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00277-022-04786-y","article-title":"Refractory primary immune thrombocytopenia (ITP): Current clinical challenges and therapeutic perspectives","volume":"101","author":"Vianelli","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MBC.0000000000000043","article-title":"Chronic immune thrombocytopenia in childhood","volume":"25","author":"Accettura","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.2021010968","article-title":"How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment","volume":"137","author":"Ghanima","year":"2021","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/bloodadvances.2017009860","article-title":"Management of newly diagnosed immune thrombocytopenia: Can we change outcomes?","volume":"1","author":"Neunert","year":"2017","journal-title":"Blood Adv."},{"key":"ref_10","unstructured":"National Institute for Health and Care Excellence (2023, December 12). Fostamatinib for Treating Refractory Chronic Immune Thrombocytopenia. Available online: https:\/\/www.nice.org.uk\/guidance\/ta835."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","article-title":"Mechanisms and therapeutic prospects of thrombopoietin receptor agonists","volume":"56","author":"Bussel","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000528642","article-title":"Efficacy and incidence of treatment related adverse events of thrombopoietin receptor agonists in adults with immune thrombocytopenia: A systematic review and network meta-analysis of randomized controlled study","volume":"146","author":"Liu","year":"2023","journal-title":"Acta. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s12325-021-01752-4","article-title":"Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: A systematic literature review and network meta-analysis","volume":"38","author":"Wojciechowski","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/09537104.2018.1543864","article-title":"Comparison of treatments for persistent\/chronic immune thrombocytopenia: A systematic review and network meta-analysis","volume":"30","author":"Arai","year":"2019","journal-title":"Platelets"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/09537104.2020.1745168","article-title":"Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: A meta-analysis and systematic review","volume":"32","author":"Birocchi","year":"2021","journal-title":"Platelets"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Deng, J., Hu, H., Huang, F., Huang, C., Huang, Q., Wang, L., Wu, A., Yang, J., Qin, D., and Zou, W. (2021). Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.704093"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14656566.2023.2198089","article-title":"Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: A meta-analysis","volume":"24","author":"Li","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/etm.2023.12092","article-title":"Safety of non-peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta-analysis of short-term double-blind randomized clinical trials","volume":"26","author":"Shen","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/16078454.2019.1568659","article-title":"Therapeutic options for adult patients with previously treated immune thrombocytopenia\u2014A systematic review and network meta-analysis","volume":"24","author":"Yang","year":"2019","journal-title":"Hematology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhang, J., Liang, Y., Ai, Y., Li, X., Xie, J., Li, Y., Zheng, W., and He, R. (2018). Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198504"},{"key":"ref_21","unstructured":"National Institute for Health and Care Excellence (2023, April 30). Romiplostim for the Treatment of Chronic Immune Thrombocytopenia. Technology Appraisal Guidance [TA221]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta221."},{"key":"ref_22","unstructured":"National Institute for Health and Care Excellence (2023, December 12). Eltrombopag for Treating Chronic Immune Thrombocytopenia. Technology Appraisal Guidance [TA293]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta293."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jval.2016.03.1856","article-title":"Cost-effectiveness of eltrombopag versus romiplostim for the treatment of chronic immune thrombocytopenia in England and Wales","volume":"19","author":"Allen","year":"2016","journal-title":"Value Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40258-013-0044-y","article-title":"Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland","volume":"11","author":"Lee","year":"2013","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_25","unstructured":"National Institute for Health and Care Excellence (2023, October 31). NICE Health Technology Evaluations: The Manual. Available online: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"ref_29","unstructured":"NHS England (2023, June 30). 2019\/20 National Cost Collection Data Publication, Available online: https:\/\/www.england.nhs.uk\/publication\/2019-20-national-cost-collection-data-publication\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/16078454.2021.1992945","article-title":"Characterization and treatment of immune thrombocytopenia in Europe: A qualitative observational study","volume":"26","author":"Pogna","year":"2021","journal-title":"Hematology"},{"key":"ref_31","unstructured":"National Health Service (2023, June 30). NHS National Tariff Workbook 2019\/2020, Available online: https:\/\/www.england.nhs.uk\/publication\/past-national-tariffs-documents-and-policies\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V116.21.68.68","article-title":"Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): Final report from an open-label extension study","volume":"116","author":"Kuter","year":"2010","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2307\/1907382","article-title":"Estimation of relationships for limited dependent variables","volume":"26","author":"Tobit","year":"1958","journal-title":"Econometrica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.21500","article-title":"Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura","volume":"84","author":"Danese","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_35","unstructured":"Office for National Statistics (2023, June 30). National Life Tables\u2014Life Expectancy in the UK: 2017 to 2019, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2017to2019."},{"key":"ref_36","unstructured":"Sobi (2015). Clinical Study Report: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard Care for the Treatment of Thrombocytopenia in Adults with Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura), Sobi."},{"key":"ref_37","unstructured":"National Institute for Health and Care Excellence (2023, December 12). Eltrombopag for Adult Patients with Chronic Immune Thrombocytopenic Purpura (cITP). Single Technology Appraisal (STA). Available online: https:\/\/www.nice.org.uk\/guidance\/ta293\/documents\/thrombocytopenic-purpura-eltrombopag-rev-ta205-glaxosmithkline4."},{"key":"ref_38","unstructured":"National Health Service (2023, June 30). NHS National Tariff Workbook 2018\/2019, Available online: https:\/\/www.england.nhs.uk\/publication\/past-national-tariffs-documents-and-policies\/."},{"key":"ref_39","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2023). Chapter 11: Undertaking Network Meta-Analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023), Cochrane. Available online: https:\/\/training.cochrane.org\/handbook\/current\/chapter-11#."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat. Med."},{"key":"ref_42","unstructured":"National Institute for Health and Care Excellence (2023, December 30). British National Formulary. Available online: https:\/\/bnf.nice.org.uk."},{"key":"ref_43","unstructured":"Sobi (2023, April 03). Summary of Product Characteristics: Doptelet (Avatrombopag). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/doptelet-epar-product-information_en.pdf."},{"key":"ref_44","unstructured":"Novartis Europharm Limited (2023, April 03). Summary of Product Characteristics: Revolade (Eltrmobopag). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revolade-epar-product-information_en.pdf."},{"key":"ref_45","unstructured":"National Institute for Health and Care Excellence (2023, April 30). Romiplostim for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura (ITP): A Single Technology Appraisal. Available online: https:\/\/www.nice.org.uk\/guidance\/ta221\/documents\/romiplostim-for-the-treatment-of-chronic-immune-or-idiopathic-thrombocytopenic-purpura-itp-a-single-technology-appraisal2."},{"key":"ref_46","unstructured":"National Institute for Health and Care Excellence (2023, May 31). Single Technology Appraisal. Avatrombopag in Combination for Treating Chronic Immune Thrombocytopenia [ID3838]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta853\/documents\/committee-papers."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"ref_48","unstructured":"JoDrugs (2023, December 12). Ethamsylate Dosing. Available online: http:\/\/www.jodrugs.com\/products\/38706-ethamsylate.aspx."},{"key":"ref_49","unstructured":"London Ambulance Service NHS Trust (2023, June 30). Annual Report & Accounts 2018\/2019, Available online: https:\/\/www.londonambulance.nhs.uk\/wp-content\/uploads\/2019\/08\/London-Ambulance-Service-Annual-Report-Accounts-2018-19.pdf."},{"key":"ref_50","unstructured":"National Institute for Health and Care Excellence (National Clinical Guideline Centre) (2023, June 30). Preoperative Tests Clinical Guideline. Available online: https:\/\/www.nice.org.uk\/guidance\/NG45\/documents\/guideline-appendices-13."},{"key":"ref_51","unstructured":"NHS Wales (2023, June 30). Together for Health\u2014A Delivery Plan for the Critically Ill, Available online: https:\/\/www.wales.nhs.uk\/documents\/Delivery-Plan-for-the-critically-ill.pdf."},{"key":"ref_52","unstructured":"University Hospitals Birmingham Trust (2023, June 30). FOI 0778 Tariff\/Cost of Bed. Available online: https:\/\/hgs.uhb.nhs.uk\/foi-0778-tariff-cost-of-bed\/."},{"key":"ref_53","unstructured":"Kessler, C.M., Latif, H., and Cunningham, J.M. (2023, June 30). Immune Thrombocytopenia (ITP). Available online: https:\/\/emedicine.medscape.com\/article\/202158-overview."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Carta, A., and Conversano, C. (2020). On the use of Markov models in pharmacoeconomics: Pros and cons and implications for policy makers. Front. Public. Health, 8.","DOI":"10.3389\/fpubh.2020.569500"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.clinthera.2020.02.020","article-title":"The cost-effectiveness of eltrombopag for the treatment of immune thrombocytopenia in the United States","volume":"42","author":"Tremblay","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_56","unstructured":"Amgen Europe, B.V. (2024, November 15). Summary of Product Characteristics: Nplate (Romiplostim). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nplate-epar-product-information_en.pdf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2040620719837906","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Godeau","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ejh.12932","article-title":"Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres","volume":"99","author":"Lakhwani","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ajh.26497","article-title":"Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia","volume":"98","author":"Goshua","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2230663","DOI":"10.1080\/20016689.2023.2230663","article-title":"Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments","volume":"11","author":"Aiello","year":"2023","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000533175","article-title":"Fostamatinib or thrombopoietin for the treatment of chronic immune thrombocytopenia in adult patients: A real-world assessment of safety, effectiveness and cost","volume":"147","author":"Dranitsaris","year":"2024","journal-title":"Acta. Haematol."},{"key":"ref_62","unstructured":"National Institute for Health and Care Excellence (2023, April 30). Avatrombopag for Treating Primary Chronic Immune Thrombocytopenia Technology Appraisal Guidance [TA853]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta853."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kurki, S., Halla-Aho, V., Haussmann, M., L\u00e4hdesm\u00e4ki, H., Leinonen, J.V., and Koskinen, M. (2024). A comparative study of clinical trial and real-world data in patients with diabetic kidney disease. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-51938-3"}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/13\/2\/11\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:59:03Z","timestamp":1760029143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/13\/2\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jmahp13020011"],"URL":"https:\/\/doi.org\/10.3390\/jmahp13020011","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}